A carregar...
Real-world experience of afatinib as a first-line therapy for advanced EGFR mutation-positive lung adenocarcinoma
We evaluated the real-world efficacy and side effects of afatinib as a first-line therapy for advanced EGFR mutation-positive lung adenocarcinoma. The medical records of patients receiving afatinib as a first-line therapy after National Health Insurance reimbursement between May 2014 and January 201...
Na minha lista:
| Publicado no: | Oncotarget |
|---|---|
| Main Authors: | , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Impact Journals LLC
2017
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5685763/ https://ncbi.nlm.nih.gov/pubmed/29163842 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.19563 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|